

IQVIA CAR T-Cell Monitor


Linking CAR T-Cell center perspectives and referring physicians in one integrated offering

CAR T-Cell Monitor delivers insights into the market dynamics in the CAR T-Cell therapy space, reflecting the collaboration practices between the CAR T sites and the referring physicians while providing a better understanding of the patient experience.

CAR T-Cell Monitor is available in France, Germany, Italy, Spain, the UK, Belgium, the US, Canada, Brazil and Japan.



CAR T-Cell therapy patient journey and the corresponding IQVIA CAR T-Cell Monitor studies




CAR T-Cell referral insights

Example analysis: referral specifications for potential Car T-Cell patients

The percentage of general referrals for the CAR T-Cell therapy class was highest in Europe (aggregated data from France, Germany, Italy, Spain, the UK, and Belgium), whereas a specific brand of the therapy class was requested most often in Japan. In the US, the CAR T-Cell therapy class was not requested at referral 27% of the time.

Source: CAR T-Cell Referral Insights for Q4 2021

Information provided when patients were referred for consultation



CAR T-Cell center insights

Example analysis: Net Promoter Scores (NPS) for Car T-Cell therapies

NPS differed by brand of CAR T-Cell therapy and country. The healthcare providers were asked to rank their likelihood of recommending the individual brands of CAR T-Cell therapies to their colleagues at a different CAR T center on a scale from 0 to 10. In an aggregated view for all therapies in EU4+UK, almost half of the HCPs (45%) were identified as promoters, whereas less than a fifth (17%) were classified as detractors, resulting in a NPS of 27%.

Source: CAR T-Cell Center Insights for Q4 2021; EU4+UK = France, Germany, Italy, Spain, the UK

Average Net Promoter Score (NPS) for approved CAR T-Cell therapies in EU4+UK

